ORIGINAL RESEARCH article
Front. Endocrinol.
Sec. Cardiovascular Endocrinology
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1653948
This article is part of the Research TopicAdvancements in Precision Medicine: Diagnostic and Prognostic Innovations for Cardiopulmonary ConditionsView all articles
Triglyceride-Glucose Index as a Novel Prognostic Biomarker for Coronary Artery Disease: Evidence from a Large-Scale Prospective Cohort Study
Provisionally accepted- 1Beijing Tiantan Hospital Department of Neurology, Beijing, China
- 2Other
- 3Chinese Academy of Medical Sciences and Peking Union Medical College Fuwai Hospital, Beijing, China
- 4Beijing Hospital, Beijing, China
- 5Beijing Anzhen Hospital Affiliated to Capital Medical University, Beijing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: The triglyceride-glucose (TyG) index, combining fasting glucose and triglyceride levels, has emerged as a promising biomarker for coronary artery disease (CAD). However, evidence for its long-term prognostic value in CAD remains inconclusive. Methods: This prospective cohort study was conducted at Beijing Hospital between January 2016 and December 2021, involving 23,591 patients with CAD. Based on the inclusion and exclusion criteria, a total of 11,325 CAD patients were included in the final analysis. TyG index was determined using the formula ln [fasting triglycerides (mg/dL) × fasting glucose. Eligible participants were stratified by TyG tertiles: Tertile 1 (TyG ≤ 8.39, n=3,775); Tertile 2 (8.40 ≤ TyG ≤ 8.92, n=3,776); Tertile 3 (TyG ≥ 8.93, n=3,774), with a median follow-up duration of 28 months. The primary outcomes were all-cause death and cardiovascular disease (CVD) death. The secondary outcome was major adverse cardiovascular events (MACE). Cox proportional hazards models and restricted cubic spline (RCS) analysis were applied to investigate the relationship between the TyG index and endpoints. Results: RCS analyses showed a monotonic increase in all-cause death, CVD death, and MACE risks with higher TyG. Kaplan-Meier curves confirmed worse survival in higher TyG tertiles. Multivariable-adjusted analysis revealed continuous TyG index was an independent risk factor for all-cause death (HR=1.22; 95% CI 1.02-1.45) and CVD death (HR=1.61; 95% CI 1.17-2.22). Using the lowest TyG index tertile as the reference (T1), the highest tertile (T3) group exhibited a 1.34-fold risk of all-cause death (95% CI 1.04-1.72), a 1.99-fold risk of CVD death (95% CI 1.23-3.21), and a 1.17-fold higher risk of MACE (95% CI 1.00-1.37), respectively. Subgroup analyses showed the continuous TyG index was significantly associated with the risk of all-cause death in acute coronary syndrome (ACS) and CVD death in chronic coronary syndrome (CCS). With T1 as the reference, patients with CCS in the T3 group had a 2.15-fold higher risk of CVD death. Conclusion: The TyG index correlates with increased all-cause death, CVD death, and MACE risks in CAD, with prognostic value in both ACS and CCS, particularly in CCS. These findings establish TyG as a robust CAD biomarker, warranting further clinical research.
Keywords: triglyceride-glucose, Coronary Artery Disease, Acute Coronary Syndrome, Chronic coronary syndrome, Mortality, Major adverse cardiovascular events
Received: 25 Jun 2025; Accepted: 28 Aug 2025.
Copyright: © 2025 Feng, Zhao, Xu, Meng, Li, Xia, ZHAO, Peng and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Zinan ZHAO, Beijing Hospital, Beijing, China
Hongyu Peng, Beijing Anzhen Hospital Affiliated to Capital Medical University, Beijing, China
Xiang Wang, Beijing Hospital, Beijing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.